Join to View Full Profile
72 E Main St Ste 1Babylon, NY 11702
Phone+1 631-751-3000
Fax+1 978-788-7966
Dr. Zuniga is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Dr. Richard Zuniga is an oncologist in Babylon, NY, specializing in hematologic and neuro-oncology. He completed his residency in internal medicine at Henry Ford Hospital and fellowships in hematology and medical oncology, drug development, and neuro-oncology. His research includes significant publications on glioblastoma and racial inequities in cancer treatment. Dr. Zuniga is actively involved in clinical trials focusing on advanced metastatic and non-small cell lung cancer treatments.
Education & Training
The University of Texas Health Science Center at San AntonioOncology, Drug Development, 2010 - 2012- University of Texas Health Science Center San Antonio Joe and Teresa Lozano Long School of MedicineFellowship, Hematology and Medical Oncology, 2009 - 2012
Henry Ford Hermelin Brain Tumor CenterNeuro-oncology, Fellowship , 2007 - 2008
Henry Ford Health/Henry Ford HospitalResidency, Internal Medicine, 2004 - 2007
University of San Martin de Porres Faculty of MedicineClass of 2003
Certifications & Licensure
NY State Medical License 2012 - 2026
MA State Medical License 2015 - 2020
TX State Medical License 2011 - 2013
MI State Medical License 2004 - 2011
American Board of Internal Medicine Medical Oncology
Clinical Trials
- Testing MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer Start of enrollment: 2017 Jan 18
- A Study to Learn if a Combination of Fianlimab and Cemiplimab Versus Cemiplimab Alone is More Effective for Adult Participants With Advanced Non-Small Cell Lung Cancer (NSCLC) Start of enrollment: 2023 Jun 30
- FIH Study of RGT-419B Alone and With Endocrine Therapy in HR-Positive, HER2-Negative Advanced/Metastatic Breast Cancer Start of enrollment: 2022 Mar 04
- Join now to see all
Publications & Presentations
PubMed
- Care Coordination for Mosunetuzumab Therapy in Patients With Follicular Lymphoma in Community Practices: Learnings From the MorningSun Study Investigators.Tara Graff, Ian Flinn, Jeff P Sharman, Steven Liu, Bertrand M Anz
Cancer Medicine. 2025-06-01 - A rising tide lifts all boats in the personalized cancer care continuum for mNSCLC: bridging inequities in NGS fosters equity in targeted treatment.Victor T G Lin, Esprit Ma, Neha Jain, Zhiyu Xia, Danny Sheinson
The Oncologist. 2025-05-08 - CLO25-071: The Impact of ChemoMouthpiece Device on Analgesic Use for Oral Pain in a Randomized, Prospective, Multi-Center Trial for Patients Undergoing Stomatoxic Chem...Vikas Dembla, Richard Zuniga
Journal of the National Comprehensive Cancer Network. 2025-03-28
Press Mentions
AACR: Topical Treatment Offers Relief from Painful Skin Rash Caused by Targeted Cancer TherapyApril 25th, 2025
Research History
- Medical Chief of ResearchNew York Cancer and Blood specialists Conducting over 40 clinical trials2021 - Present
Other Languages
- Spanish
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
